Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.30 USD
+0.03 (2.36%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NKTR 1.30 +0.03(2.36%)
Will NKTR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
What Makes Nektar (NKTR) a New Buy Stock
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Other News for NKTR
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar: Q2 Earnings Snapshot
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024